Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Balasubramanian, Anuradha ^a   Koziel, Margaret ^a   Groopman, Jerome E ^a   Ganju, Ramesh K ^a,b  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b HIM/BIDMC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 8; CYTOCHROME C; FAS LIGAND; GLYCOPROTEIN GP 120; PROTEIN BID; VIRUS ENVELOPE PROTEIN;

APOPTOSIS; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; MITOCHONDRION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SUPERINFECTION; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; FAS LIGAND PROTEIN; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HIV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; LIVER; MITOCHONDRIA, LIVER; PEPTIDE FRAGMENTS; TIME FACTORS; UP-REGULATION; VIRAL ENVELOPE PROTEINS;

EID: 20844454943     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429493     Document Type: Article

References (38)

1. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107:793-843.
2. Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol 2001; 33:367-74.
3. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92:1130-4.
4. Puoti M, Gargulio F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000; 181:2033-6.
5. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
6. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134-7.
7. Moreno A, Martinez CJ, Carreno V. Liver biopsy and the etiologic diagnosis of chronic hepatitis. J Hepatol 1993; 17:3112-5.
8. Roskams T, Libbrecht L, van Damme B, Desmet V. Fas and Fas ligand: stong co-expression in hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoral cells? J Pathol 2000; 191:150-3.
9. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296:1635-6.
10. Leithauser F. Constitutive and induced expression of Apo-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69:415-29.
11. Suda T, Takahashi T, Goldstein, P, Nagata S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
12. van Parijs L, Abbas A. Role of Fas mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996; 8:355-61.
13. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397:441-6.
14. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (Apo-1/Fas) signaling pathways. EMBO J 1998; 17:1675-87.
15. Roberts JM, Searle JW, Cooksley WG. Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn 1993; 28:37-41.
16. Daniel V, Sadeghi M, Naujokat C, et al. Evidence for autoantibody-induced CD4 depletion mediated by apoptotic and non-apoptotic mechanisms in HIV-positive long-term surviving haemophilia patients. Clin Exp Immunol 2004; 135:94-104.
17. Munshi M, Balasubramanian A, Koziel M, Ganju, RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 2003; 188:1192-204.
18. Li H, Zhu H, Xu C, Yuan J. Cleavage of bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
19. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999; 144:903-14.
20. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17:3878-85.
21. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome C release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274:1156-63.
22. Wei MC, Lindsten T, Mootha VK, et al. tBid, a membrane targeted death ligand, oligomerixes bak to release cytochrome C. Genes Dev 2000; 14:2060-71.
23. Enari M, Hug M, Nagata S. Involvement of and ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375:78-81.
24. Los M, Van de Craen M, Penning LC, et al. Requirement of ICE/CED-3 protease for Fas/Apo-1 mediated apoptosis. Nature 1995; 375:81-3.
25. Enari M, Talanian RV, Wang WW, Nagata S. Sequential activation of ICE-like and CPP32 like proteases during Fas-mediated apoptosis. Nature 1996; 380:723-6.
26. Hasegawa J, Kamada S, Kamiike W, et al. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Res 1996; 56: 1713-8.
27. Schlegel I, Peters I, Orrenius S, et al. CPP32/apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 1996; 271:1841-4.
28. Kamada S, Washida M, Hasegawa J, Kusano H, Funahashi Y, Tsujimoto Y. Involvement of caspase-4(like) protease in Fas-mediated apoptotic pathway. Oncogene 1997; 15:285-90.
29. Takahashi A, Hirata H, Yonehara S, et al. Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine and CrmA sensitive caspase-8. Oncogene 1997; 14:2741-52.
30. Fernandes-Alnemri T, Takahashi A, Armstrong S, et al. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res 1995; 55:6045-52.
31. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-8.
32. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
33. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in fas-induced apoptosis. J Exp Med 1998; 187:587-600.
34. Galle PR, Hofmann WJ, Wakzak H, et al. Involvement of CD45 (Apo-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-30.
35. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13:1899-911.
36. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400:886-91.
37. Rodriguez I, Matsuura K, Khatib K, et al. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 1996; 183:1031-6.
38. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15:185-93.